Drugs / Universal CD19 CAR-γδT Cell Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07526493 | Apr 2026 → Dec 2027 expected | autoimmune encephalitis, chronic inflammatory demyelinating polyradiculoneuropathy, idiopathic inflammatory myopathy, multiple sclerosis +3 | Tongji Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Universal CD19 CAR-γδT Cell Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07526493 ↗ |
| Modality | Cell therapy | “Allogeneic CD19 CAR-γδT cell” NCT07526493 ↗ |
| Target | CD19 | “Allogeneic CD19 CAR-γδT cell” NCT07526493 ↗ |